Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) ...

USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Additionally, the trial met all secondary endpoints, demonstrating significant improvement with semaglutide vs placebo in pain-free walking distance (ETR: 1.11 [95% CI, 1.03-1.20; P =.0046 ...

Overall, patients in the semaglutide arm had a median improvement in walking distance of 26 meters and an average improvement of 40 meters, representing a statistically significant 13% improvement ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Researchers report yet another positive finding for GLP-1s. The participants in this trial had lower BMIs than the participants in the many other trials that have shown the benefits of the GLP-1s.

PAD is considered the first and most frequent manifestation of cardiovascular disease in patients with diabetes. There are few therapeutic and interventional options for patients ...